alzheimers research 4x3

Summary List Placement

Hello,

Welcome to Insider Healthcare. I’m Lydia Ramsey Pflanzer, and this week in healthcare news:

A controversial Alzheimer’s drug approval poses some big challenges for the future of the field;

We chronicled the history of Noom, which raised $540 million from top investors after spending a decade trying to crack the weight-loss app business;

Amazon and Walmart face off on discounting prescriptions.

If you’re new to this newsletter, sign up here. Tips, comments? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let’s get to it…

We’re still looking for nominees for our annual 30 under 40 list! 

Know someone under 40 transforming the healthcare industry? Submit their name here. Nominations are due by June 30.

A massive — and controversial — Alzheimer’s drug approval

Wow, I can’t believe it was just this Monday that the Food and Drug Administration approved the first new Alzheimer’s treatment in nearly two decades.

There were a few surprises that came with the approval of the drug, Aduhelm. For one, there were no real limitations placed by FDA on who will be eligible for the new drug. And the drug costs roughly $56,000 a year. 

…. And let’s not forget this is a drug that an expert panel voted against approving last November.

Allison DeAngelis and Shelby Livingston this week dug into a little-known barrier could stand in the way of millions of patients clamoring to get the treatment.

Since the approval, doctors have started resigning from the FDA’s expert panel — the one that voted against approving the drug. 

Allison and Andrew Dunn analyzed the problems facing Aduhelm — and future Alzheimer’s drugs. 

Find out more>>
The first new Alzheimer’s drug in decades costs $56,000, probably doesn’t work, and could stand in the way of better treatments

Source:: Business Insider

      

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *